Tecentriq Hybreza |
761347 |
001 |
351(a) |
atezolizumab and hyaluronidase-tqjs |
Injection |
Subcutaneous |
1,875MG/15ML; 30,000UNITS/15ML (125MG/2,000UNITS/ML) |
Single-Dose Vial |
2024/09/12
|
Genentech, Inc. |
Rx |
Licensed |
|
|
Tremfya |
761061 |
003 |
351(a) |
guselkumab |
Injection |
Subcutaneous |
200MG/2ML (100MG/ML) |
Autoinjector |
2024/09/11
|
Janssen Biotech, Inc. |
Rx |
Licensed |
|
|
Tremfya |
761061 |
004 |
351(a) |
guselkumab |
Injection |
Subcutaneous |
200MG/2ML (100MG/ML) |
Pre-Filled Syringe |
2024/09/11
|
Janssen Biotech, Inc. |
Rx |
Licensed |
|
|
Tremfya |
761061 |
005 |
351(a) |
guselkumab |
Injection |
Intravenous |
200MG/20ML (10MG/ML) |
Single-Dose Vial |
2024/09/11
|
Janssen Biotech, Inc. |
Rx |
Licensed |
|
|
Hercessi |
761346 |
002 |
351(k) Biosimilar |
trastuzumab-strf |
For Injection |
Intravenous |
420MG |
Multi-Dose Vial |
2024/09/06
|
Accord BioPharma Inc. |
Rx |
Licensed |
trastuzumab |
Herceptin |
Pavblu |
761298 |
001 |
351(k) Biosimilar |
aflibercept-ayyh |
Injection |
Intravitreal |
2MG/0.05ML |
Single-Dose Vial |
2024/08/23
|
Amgen Inc. |
Rx |
Licensed |
aflibercept |
Eylea |
Pavblu |
761298 |
002 |
351(k) Biosimilar |
aflibercept-ayyh |
Injection |
Intravitreal |
2MG/0.05ML |
Pre-Filled Syringe |
2024/08/23
|
Amgen Inc. |
Rx |
Licensed |
aflibercept |
Eylea |
Taltz |
125521 |
003 |
351(a) |
ixekizumab |
Injection |
Subcutaneous |
40MG/0.5ML |
Pre-Filled Syringe |
2024/08/20
|
Eli Lilly and Company |
Rx |
Licensed |
|
|
Taltz |
125521 |
004 |
351(a) |
ixekizumab |
Injection |
Subcutaneous |
20MG/0.25ML |
Pre-Filled Syringe |
2024/08/20
|
Eli Lilly and Company |
Rx |
Licensed |
|
|
Niktimvo |
761411 |
001 |
351(a) |
axatilimab-csfr |
Injection |
Intravenous |
50MG/ML |
Single-Dose Vial |
2024/08/14
|
Incyte Corporation |
Rx |
Licensed |
|
|
Nemluvio |
761390 |
001 |
351(a) |
nemolizumab-ilto |
For Injection |
Subcutaneous |
30MG |
Autoinjector |
2024/08/12
|
Galderma Laboratories, L.P. |
Rx |
Licensed |
|
|
Zarxio |
125553 |
003 |
351(k) Biosimilar |
filgrastim-sndz |
Injection |
Intravenous, Subcutaneous |
300MCG/ML |
Single-Dose Vial |
2024/08/09
|
Sandoz Inc. |
Disc |
Licensed |
filgrastim |
Neupogen |
Zarxio |
125553 |
004 |
351(k) Biosimilar |
filgrastim-sndz |
Injection |
Intravenous, Subcutaneous |
480MCG/1.6ML (300MCG/ML) |
Single-Dose Vial |
2024/08/09
|
Sandoz Inc. |
Disc |
Licensed |
filgrastim |
Neupogen |
Enzeevu |
761382 |
001 |
351(k) Biosimilar |
aflibercept-abzv |
Injection |
Intravitreal |
2MG/0.05ML |
Single-Dose Vial |
2024/08/09
|
Sandoz Inc. |
Rx |
Licensed |
aflibercept |
Eylea |
Enzeevu |
761382 |
002 |
351(k) Biosimilar |
aflibercept-abzv |
Injection |
Intravitreal |
2MG/0.05ML |
Pre-Filled Syringe |
2024/08/09
|
Sandoz Inc. |
Rx |
Licensed |
aflibercept |
Eylea |
Lymphir |
761312 |
001 |
351(a) |
denileukin diftitox-cxdl |
For Injection |
Intravenous |
300MCG |
Single-Dose Vial |
2024/08/07
|
Citius Pharmaceuticals, Inc. |
Rx |
Licensed |
|
|
tecelra |
125789 |
001 |
351(a) |
afamitresgene autoleucel |
Suspension |
Intravenous |
2.68 x 10^9 to 10 x 10^9 CELL/ML |
Bag |
2024/08/01
|
Adaptimmune LLC |
Rx |
Licensed |
|
|
Epysqli |
761340 |
001 |
351(k) Biosimilar |
eculizumab-aagh |
Injection |
Intravenous |
300MG/30ML (10MG/ML) |
Single-Dose Vial |
2024/07/19
|
Samsung Bioepis Co., Ltd. |
Rx |
Licensed |
eculizumab |
Soliris |
Vabysmo |
761235 |
002 |
351(a) |
faricimab-svoa |
Injection |
Intravitreal |
6MG/0.05ML (120MG/ML) |
Pre-Filled Syringe |
2024/07/09
|
Genentech, Inc. |
Rx |
Licensed |
|
|
Kisunla |
761248 |
001 |
351(a) |
donanemab-azbt |
Injection |
Intravenous |
350MG/20ML (17.5MG/ML) |
Single-Dose Vial |
2024/07/02
|
Eli Lilly and Company |
Rx |
Licensed |
|
|